New Ventures Funds - Investor Profile and Portfolio

Developer of precision breeding technologies for resilient and vigorous crops. The company focuses on creating crops with specific traits to withstand environmental stressors. It works with agricultural partners to develop seeds resistant to heat, pests, fungus, and weeds. The goal is to produce crops that require fewer chemicals and less energy.

Sprout Pharmaceuticals has developed drugs for women's health. The company has developed an FDA-approved non-hormonal pill called ADDYI to cure Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.

Pharmaceutical company developing a novel rescue drug for ulcerative colitis flares. Focused on gastroenterology, the company addresses unmet needs in disease management with a low competitive landscape. Their lead product, completing Phase 3 trials, aims for clinical remission with mucosal healing in just four weeks, offering a unique rescue option for ulcerative colitis patients, alone or with maintenance therapies. The company's patented suppository, utilizing a novel hydrocortisone acetate formulation and applicator, ensures consistent drug delivery and eliminates leakage. With a strong IP portfolio extending market exclusivity, they are poised to provide relief from debilitating rectal symptoms and improve the quality of life for those living with ulcerative colitis. This innovative approach solves an unmet need in ulcerative colitis treatment.

VERIGRAFT is developing personalized tissue-engineered transplants. The company is using is regenerative medicine technology to develop biological transplants that are free from immunosuppression and infections. The company has completed preclinical tests for personalized tissue-engineered veins (P-TEV). The product is being tested for chronic venous insufficiency.